View in Other Languages

Ranbaxy Laboratories Limited

BOM:500359 ISIN:INE015A01028

Ranbaxy Laboratories Limited (RLL), along with its subsidiaries and associates operates as an integrated international pharmaceutical organization with businesses encompassing the entire value chain in the production, marketing and distribution of dosage forms and active pharmaceutical ingredients. It has manufacturing facilities in 11 countries, namely Brazil, China, India, Ireland, Japan, Malaysia, Nigeria, Romania, South Africa, the United States and Vietnam. Its major markets include the United States, India, Europe, Russia / CIS, Brazil and South Africa. The major products include, inter alia, Simvastatin, CoAmoxyclav, Amoxycillin, Ciprofloxacin, Isotretinon and Cephalexin. Its research and development activities are principally carried out at its facilities in Gurgaon, near New Delhi, India. RLL’s segments include Pharmaceuticals and Other businesses. In November 2008, Daiichi Sankyo Co., Ltd. completed the takeover of RLL by buying a 63.9% stake.

  

News

Asian Activities Report for December 7, 2011: Great Wall Motors (HKG:2333) Receives EU Whole Vehicle Type Approval for Voleex C30 and Voleex C20R

🕔12/7/2011 11:27:21 AM 7501

Asian Activities Report for December 7, 2011 includes: Great Wall Motors (HKG:2333) has received EU Whole Vehicle Type Approval for its Voleex C30 and Voleex C20R; Chevalier International Holdings Limited (HKG:0025) has entered into a letter of intent in relation to possible acquisitions of certain hot spring hotels in Japan; Daiichi Sankyo Co., Ltd (TYO:4568) advises that its subsidiary Ranbaxy Laboratories Ltd. (BOM:500359), India's largest pharmaceutical company, has received final approval from the U.S. Food and Drug Administration to manufacture and market Atorvastatin, a cholesterol-reducing medicine, in the US market.

Read Full Article

Asian Activities Report for September 1, 2011: CBD Energy (ASX:CBD) Signs Management Agreement with the AusChina Energy Joint Venture

🕔9/1/2011 12:00:32 PM 9823

Asian Activities Report for September 1, 2011 includes: CBD Energy (ASX:CBD) has signed an agreement to participate in the management of the AusChina Energy Joint Venture; TVN Corporation Pty Ltd (ASX:TVN) announced the results from its latest drilling on the Nuurst Project in Mongolia; Uran Limited (ASX:URA) has commenced commercial open pit mining activities at the Emmanuel Project in Zambia; Aviva Corporation Limited (ASX:AVA) has recently completed a maiden resource estimate on the Bumbo Base Metal Deposit in West Kenya; Manas Resources Limited (ASX:MSR) has completed a 12,500 metre drilling program at Shambesai Gold Project in the Kyrgyz Republic; Daiichi Sankyo Company, Limited (TYO:4568) and Ranbaxy Laboratories Limited (BOM:500359) today announced a joint initiative to sponsor mobile healthcare clinics in India, Cameroon and Tanzania.

Read Full Article

Asian Markets Overview of December 9

🕔12/9/2009 1:30:25 PM 17354

US stocks fell on Tuesday on disappointing corporate news and renewed worries over global credit markets. Asian stocks mostly opened lower today with Australian and Japanese markets slashed sharply at opening.

Read Full Article

Australian Market Report of January 22: Helped by Short Selling Ban

🕔1/22/2009 1:00:28 PM 14922

Yesterday the Australian stock market ended the day lower, led by financial stocks, on renewed worries about banking industry worldwide. The benchmark S&P/ASX200 index was down 1%, or 33.8 points, at 3442.8, while the broader All Ordinaries index was lower by 0.9%, or 30.2 points, at 3394.8. Regulator ASIC's move to extend a ban on covered short-selling of financial securities would give a positive lead to the banking industry.

Read Full Article
###

83,842 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 22) (Last 30 Days: 47) (Since Published: 13496) 

Company Data

    Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.ranbaxy.com

Social Media